40 results on '"Zhang, Guojing"'
Search Results
2. The subsonic or sonic–subsonic solution of the electric potential driven problem to the HD model for semiconductors
- Author
-
Li, Siying, Zhang, Kaijun, and Zhang, Guojing
- Published
- 2024
- Full Text
- View/download PDF
3. External magnetic field have significant effects on diversity of magnetotactic bacteria in sediments from Yangtze River, Chagan Lake and Zhalong Wetland in China
- Author
-
Zhang, Guojing, Liu, Tao, Zhao, Dan, Sun, Xindi, Xing, Weijia, Zhang, Shuang, and Yan, Lei
- Published
- 2023
- Full Text
- View/download PDF
4. Biomineralization and biotechnological applications of bacterial magnetosomes
- Author
-
Ying, Gaofei, Zhang, Guojing, Yang, Jiani, Hao, Ziyu, Xing, Weijia, Lu, Dong, Zhang, Shuang, and Yan, Lei
- Published
- 2022
- Full Text
- View/download PDF
5. Causes and statistical characteristics of bridge failures: A review
- Author
-
Zhang, Guojing, Liu, Yongjian, Liu, Jiang, Lan, Shiyong, and Yang, Jian
- Published
- 2022
- Full Text
- View/download PDF
6. Understanding EUV mask blank surface roughness induced LWR and associated roughness requirement:
- Author
-
Yan, Pei-Yang, Zhang, Guojing, Gullikson, Eric, M., Goldberg, Kenneth, A., and Benk, Markus, P.
- Published
- 2017
7. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
- Author
-
Owonikoko, Taofeek K., Dwivedi, Bhakti, Chen, Zhengjia, Zhang, Chao, Barwick, Benjamin, Ernani, Vinicius, Zhang, Guojing, Gilbert-Ross, Melissa, Carlisle, Jennifer, Khuri, Fadlo R., Curran, Walter J., Ivanov, Andrey A., Fu, Haian, Lonial, Sagar, Ramalingam, Suresh S., Sun, Shi-Yong, Waller, Edmund K., and Sica, Gabriel L.
- Published
- 2021
- Full Text
- View/download PDF
8. Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance
- Author
-
Pan, Chaoyun, Jin, Lingtao, Wang, Xu, Li, Yuancheng, Chun, Jaemoo, Boese, Austin C., Li, Dan, Kang, Hee-Bum, Zhang, Guojing, Zhou, Lu, Chen, Georgia Z., Saba, Nabil F., Shin, Dong M., Magliocca, Kelly R., Owonikoko, Taofeek K., Mao, Hui, Lonial, Sagar, and Kang, Sumin
- Subjects
Oxidases -- Physiological aspects ,Inositol -- Physiological aspects ,B cells -- Physiological aspects ,Chemotherapy -- Physiological aspects ,Medical research -- Physiological aspects ,Antineoplastic agents -- Physiological aspects ,Cancer research ,Cancer ,Homeostasis ,Tumors ,Cancer cells ,RNA interference ,Enzymes ,Health care industry - Abstract
How altered metabolism contributes to chemotherapy resistance in cancer cells remains unclear. Through a metabolism-related kinome RNAi screen, we identified inositol-trisphosphate 3-kinase B (ITPKB) as a critical enzyme that contributes to cisplatin-resistant tumor growth. We demonstrated that inositol 1,3,4,5- tetrakisphosphate (IP4), the product of ITPKB, plays a critical role in redox homeostasis upon cisplatin exposure by reducing cisplatin-induced ROS through inhibition of a ROS-generating enzyme, NADPH oxidase 4 (NOX4), which promotes cisplatin- resistant tumor growth. Mechanistically, we identified that IP4 competes with the NOX4 cofactor NADPH for binding and consequently inhibits NOX4. Targeting ITPKB with shRNA or its small-molecule inhibitor resulted in attenuation of NOX4 activity, imbalanced redox status, and sensitized cancer cells to cisplatin treatment in patient-derived xenografts. Our findings provide insight into the crosstalk between kinase-mediated metabolic regulation and platinum-based chemotherapy resistance in human cancers. Our study also suggests a distinctive signaling function of IP4 that regulates NOX4. Furthermore, pharmaceutical inhibition of ITPKB displayed synergistic attenuation of tumor growth with cisplatin, suggesting ITPKB as a promising synthetic lethal target for cancer therapeutic intervention to overcome cisplatin resistance., Introduction Cisplatin kills rapidly dividing cells by damaging their DNA and plays a crucial role in the chemotherapy of human cancers (1-3). Nevertheless, cisplatin is often accompanied by side effects, [...]
- Published
- 2019
- Full Text
- View/download PDF
9. Global existence and exponential stability for the compressible Navier–Stokes equations with discontinuous data
- Author
-
Kong, Huihui, Li, Hai-Liang, Liang, Chuangchuang, and Zhang, Guojing
- Published
- 2017
- Full Text
- View/download PDF
10. Static EUV microexposures using the ETS Set-2 optics
- Author
-
Naulleau, Partick, Goldberg, Kenneth A., Anderson, Erik H., Bokor, Jeffrey, Harteneck, Bruce, Jackson, Keith, Olynick, Deirdre, Salmassi, Farhad, Baker, Sherry, Mirkarimi, Paul, Spiller, Eberhard, Walton, Chris, O'Connell, Donna, Yan, Pei-Yang, and Zhang, Guojing
- Published
- 2003
11. Lithographic characterization of the printability of programmed EUV substrate defects
- Author
-
Naulleau, Patrick, Goldberg, Kenneth A., Anderson, Erik H., Bokor, Jeffrey, Gullikson, Eric, Harteneck, Bruce, Jackson, Keith, Olynick, Deirdre, Salmassi, Farhad, Baker, Sherry, Mirkarimi, Paul, Spiller, Eberhard, Walton, Chris, and Zhang, Guojing
- Published
- 2002
12. ASYMPTOTIC BEHAVIOR OF ROBIN PROBLEM FOR HEAT EQUATION ON A COATED BODY
- Author
-
LI, JINGYU, WANG, XUEFENG, ZHANG, GUOJING, and ZHANG, KAIJUN
- Published
- 2012
13. Optimal decay rate of the non-isentropic compressible Navier–Stokes–Poisson system in [formula omitted]
- Author
-
Zhang, Guojing, Li, Hai-Liang, and Zhu, Changjiang
- Published
- 2011
- Full Text
- View/download PDF
14. Semiclassical and relaxation limits of bipolar quantum hydrodynamic model for semiconductors
- Author
-
Zhang, Guojing, Li, Hai-Liang, and Zhang, Kaijun
- Published
- 2008
- Full Text
- View/download PDF
15. Biochemical Characterization of Two Rhamnogalacturonan Lyases From Bacteroides ovatus ATCC 8483 With Preference for RG-I Substrates.
- Author
-
Wang, Weiyang, Wang, Yibing, Yi, Haoting, Liu, Yang, Zhang, Guojing, Zhang, Le, Mayo, Kevin H., Yuan, Ye, and Zhou, Yifa
- Subjects
LYASES ,BACTEROIDES ,PECTINS ,DEGREE of polymerization ,OLIGOSACCHARIDES ,METAL ions - Abstract
Rhamnogalacturonan lyase (RGL) cleaves backbone α-1,4 glycosidic bonds between L-rhamnose and D-galacturonic acid residues in type I rhamnogalacturonan (RG-I) by β-elimination to generate RG oligosaccharides with various degrees of polymerization. Here, we cloned, expressed, purified and biochemically characterized two RGLs (Bo3128 and Bo4416) in the PL11 family from Bacteroides ovatus ATCC 8483. Bo3128 and Bo4416 displayed maximal activity at pH 9.5 and pH 6.5, respectively. Whereas the activity of Bo3128 could be increased 1.5 fold in the presence of 5 mM Ca
2+ , Bo4416 required divalent metal ions to show any enzymatic activity. Both of RGLs showed a substrate preference for RG-I compared to other pectin domains. Bo4416 and Bo3128 primarily yielded unsaturated RG oligosaccharides, with Bo3128 also producing them with short side chains, with yields of 32.4 and 62.4%, respectively. Characterization of both RGLs contribute to the preparation of rhamnogalacturonan oligosaccharides, as well as for the analysis of the fine structure of RG-I pectins. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
16. Analytical Solutions for Girder Distribution Factor in Steel-Concrete Composite Girders with the Effect of Parapets.
- Author
-
Zhang, Zejun, Liu, Yongjian, Feng, Bowen, Ma, Yinping, and Zhang, Guojing
- Subjects
STEEL-concrete composites ,ANALYTICAL solutions ,RETRIEVAL practice ,BRIDGE testing ,GIRDERS - Abstract
The existing studies have shown that parapets have great influence on the girder distribution factor (GDF) of bridges. However, there is no method in the design guide to estimate the GDF considering the effect of parapets. This research aims to develop a simplified method for estimating the GDF by considering the effect of parapets. First, a simply supported steel-concrete composite girder bridge was tested to investigate the effect of parapets on the GDF. Then, finite-element (FE) model was established and verified by the field test data of strain and deflection. In addition, error study showed that the bending stiffness of the bridge was increased by about 92% and 19.1%, respectively, due to the effects of parapet and continuous layer. As the effect of the continuous layer on each girder was relatively uniform, the simplified method was optimized only considering the effect of the parapet. Finally, the effect of the parapet on the GDF was compared and discussed. Considering the effect of the parapet, the GDF of the exterior girder calculated by the simplified method and FE analysis decreased by about 26.92% and 23.53%, respectively, and the adjacent interior girder decreased by about 15.22% and 12.77%, respectively. Comparing the GDF calculated by the AASHTO LRFD specifications, the GDF calculated by the simplified method decreased by about 30.77% in the exterior girder and 41.30% in the interior girder, respectively. The results indicate that the method of calculating the GDF without considering the effect of the parapet in AASHTO LRFD specifications is conservative. The GDF calculated by the simplified method was basically close to the field test results, meaning that the proposed simplified method considering the effect of the parapet was relatively accurate. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
- Author
-
Owonikoko, Taofeek K., Zhang, Guojing, Lallani, Shenila B., Chen, Zhengjia, Martinson, Deborah E., Khuri, Fadlo R., Lonial, Sagar, Marcus, Adam, and Sun, Shi-Yong
- Subjects
- *
EVEROLIMUS , *THYROID cancer treatment , *XENOGRAFTS , *SOMATOSTATIN receptors , *INVERSE relationships (Mathematics) - Abstract
Background: Signaling through mTOR and somatostatin pathway is implicated in thyroid cancer development. Method: We evaluated everolimus, an mTOR inhibitor and pasireotide, a multi receptor somatostatin analogue as potential therapy of thyroid cancer focusing on the in vitro and in vivo efficacy, as well as possible mechanism to explain any observed interaction. Results: Both everolimus and pasireotide inhibit the growth of thyroid cancer cell lines in vitro with varied efficacy that correlates with tumor origin and somatostatin receptor (SSTR) expression profile of the cell lines. In vitro activity of everolimus show positive correlation with the expression of SSTR types 1, 4 and 5 (CC: 0.9; 0.85, 0.87) while pasireotide activity show negative correlation with SSTR2 (CC: -0.87). Although there is greater modulation of pS6 when pasireotide is combined with everolimus, there is no significant abrogation of the expected feedback upregulation of AKT induced by everolimus. Also, the combination is not significantly better than each agent alone in short and long term in vitro assays. Continuous administration of everolimus at a low dose as opposed to high intermittent dosing schedule has greater antitumor efficacy against thyroid cancer xenografts in vivo. Pasireotide LAR has modest in vivo efficacy and the combination of everolimus and pasireotide LAR achieve greater tumor growth inhibition than each agent alone in TPC-1 xenograft model of thyroid cancer (p = 0.048). Conclusion: Our findings provide support for the clinical evaluation of everolimus and pasireotide in thyroid cancer and other neuroendocrine tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
- Author
-
Owonikoko, Taofeek K., Guojing Zhang, Kim, Hyun S., Stinson, Renea M., Bechara, Rabih, Chao Zhang, Zhengjia Chen, Saba, Nabil F., Pakkala, Suchita, Pillai, Rathi, Xingming Deng, Shi-Yong Sun, Rossi, Michael R., Sica, Gabriel L., Ramalingam, Suresh S., Khuri, Fadlo R., Zhang, Guojing, Zhang, Chao, Chen, Zhengjia, and Deng, Xingming
- Subjects
SMALL cell lung cancer ,XENOGRAFTS ,ARSENIC trioxide ,CLINICAL trials ,IMMUNOHISTOCHEMISTRY ,ANTINEOPLASTIC agents ,CISPLATIN ,ANIMAL experimentation ,ARSENIC compounds ,CANCER relapse ,CELL lines ,COMPARATIVE studies ,CONNECTIVE tissues ,ELECTROPHORESIS ,LUNG cancer ,LUNG tumors ,RESEARCH methodology ,MEDICAL cooperation ,MICE ,PROTEINS ,OXIDES ,RESEARCH ,RESEARCH funding ,EVALUATION research ,TREATMENT effectiveness ,THERAPEUTICS - Abstract
Background: SCLC has limited treatment options and inadequate preclinical models. Promising activity of arsenic trioxide (ASO) recorded in conventional preclinical models of SCLC supported the clinical evaluation of ASO in patients. We assessed the efficacy of ASO in relapsed SCLC patients and in corresponding patient-derived xenografts (PDX).Methods: Single arm, Simon 2-stage, phase II trial to enroll patients with relapsed SCLC who have failed at least one line of therapy. ASO was administered as an intravenous infusion over 1-2 h daily for 4 days in week 1 and for 2 days in weeks 2-6 of an 8-week cycle. Treatment continued until disease progression. Pretreatment tumor biopsy was employed for PDX generation through direct implantation into subcutaneous pockets of SCID mice without in vitro manipulation and serially propagated for five generations. Ex vivo efficacy of cisplatin (3 mg/kg i.p. weekly) and ASO (3.75 mg/kg i.p. every other day) was tested in PDX representative of platinum sensitive and platinum refractory SCLC.Results: The best response in 17 evaluable patients was stable disease in 2 (12 %), progressive disease in 15 (88 %) patients and median time-to-progression of seven (range 1-7) weeks. PDX was successfully grown in 5 of 9 (56 %) transplanted biopsy samples. Serially-propagated PDXs preserved characteristic small cell histology and genomic stability confirmed by immunohistochemistry, short tandem repeat (STR) profiling and targeted sequencing. ASO showed in vitro cytotoxicity but lacked in vivo efficacy against SCLC PDX tumor growth.Conclusions: Cisplatin inhibited growth of PDX derived from platinum-sensitive SCLC but was ineffective against PDX from platinum-refractory SCLC. Strong concordance between clinical and ex vivo effects of ASO and cisplatin in SCLC supports the use of PDX models to prescreen promising anticancer agents prior to clinical testing in SCLC patients. Trial Registration The study was registered at http://www.clinicaltrials.gov (NCT01470248). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
19. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.
- Author
-
Alese, Olatunji B., El-Rayes, Bassel F., Sica, Gabriel, Zhang, Guojing, Alexis, Dianne, La Rosa, Francisco G., Varella-Garcia, Marileila, Chen, Zhengjia, Rossi, Michael R., Adsay, Nazim V., Khuri, Fadlo R., and Owonikoko, Taofeek K.
- Published
- 2015
- Full Text
- View/download PDF
20. Poly ( ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
- Author
-
Owonikoko, Taofeek K., Zhang, Guojing, Deng, Xingming, Rossi, Michael R., Switchenko, Jeffrey M., Doho, Gregory H., Chen, Zhengjia, Kim, Sungjin, Strychor, Sandy, Christner, Susan M., Beumer, Jan, Li, Chunyang, Yue, Ping, Chen, Alice, Sica, Gabriel L., Ramalingam, Suresh S., Kowalski, Jeanne, Khuri, Fadlo R., and Sun, Shi‐Yong
- Subjects
- *
ENZYME inhibitors , *CANCER treatment , *SMALL cell lung cancer , *CANCER chemotherapy , *POLYMERASES , *CISPLATIN , *ETOPOSIDE , *CARBOPLATIN - Abstract
Poly ( ADP) ribose polymerase ( PARP) plays a key role in DNA repair and is highly expressed in small cell lung cancer ( SCLC). We investigated the therapeutic impact of PARP inhibition in SCLC. In vitro cytotoxicity of veliparib, cisplatin, carboplatin, and etoposide singly and combined was determined by MTS in 9 SCLC cell lines (H69, H128, H146, H526, H187, H209, DMS53, DMS153, and DMS114). Subcutaneous xenografts in athymic nu/nu mice of H146 and H128 cells with relatively high and low platinum sensitivity, respectively, were employed for in vivo testing. Mechanisms of differential sensitivity of SCLC cell lines to PARP inhibition were investigated by comparing protein and gene expression profiles of the platinum sensitive and the less sensitive cell lines. Veliparib showed limited single-agent cytotoxicity but selectively potentiated (≥50% reduction in IC50) cisplatin, carboplatin, and etoposide in vitro in five of nine SCLC cell lines. Veliparib with cisplatin or etoposide or with both cisplatin and etoposide showed greater delay in tumor growth than chemotherapy alone in H146 but not H128 xenografts. The potentiating effect of veliparib was associated with in vitro cell line sensitivity to cisplatin ( CC = 0.672; P = 0.048) and DNA- PKcs protein modulation. Gene expression profiling identified differential expression of a 5-gene panel ( GLS, UBEC2, HACL1, MSI2, and LOC100129585) in cell lines with relatively greater sensitivity to platinum and veliparib combination. Veliparib potentiates standard cytotoxic agents against SCLC in a cell-specific manner. This potentiation correlates with platinum sensitivity, DNA- PKcs expression and a 5-gene expression profile. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Plasma S100β and neuron-specific enolase, but not neuroglobin, are associated with early cognitive dysfunction after total arch replacement surgery: A pilot study.
- Author
-
Wan, Zilin, Li, Yaxiong, Ye, Huishun, Zi, Yunfeng, Zhang, Guojing, and Wang, Xiaoyan
- Published
- 2021
- Full Text
- View/download PDF
22. Differential Regulation of Anthocyanin Synthesis in Apple Peel under Different Sunlight Intensities.
- Author
-
Chen, Weifeng, Zhang, Mengxia, Zhang, Guojing, Li, Pengmin, and Ma, Fengwang
- Subjects
ANTHOCYANINS ,MICHAELIS-Menten equation ,SUNSHINE ,APPLES ,CYANIDIN ,FRUIT skins - Abstract
Sunlight radiation is a main environmental factor which affects anthocyanin synthesis. To clarify the regulatory mechanism of sunlight on the synthesis of anthocyanin in apple peel, bagged apples were exposed to diverse intensities of sunlight through different shading treatments. Under an increased solar ultraviolet-B (UV-B) light intensity, the concentration of anthocyanin in apple peels was consistent with the Michaelis–Menten equation. Under lower sunlight intensities, diphenyleneiodonium chloride (DPI, an inhibitor of plasma membrane NAD(P)H oxidase) treatment increased both the concentration of cyanidin-3-glycoside and the activity of dihydroflavonol 4-reductase (DFR). However, under higher sunlight intensities, DPI treatment decreased the concentrations of cyanidin-3-glycoside and quercetin-3-glycoside, as well as the activities of DFR and UDP-glycose: flavonoid 3-O-glycosyltransferase (UFGT). These results indicate that, under low sunlight intensity, anthocyanin synthesis in apple peel was limited by the supply of the substrate cyanidin, which was regulated by the DFR activity. Nevertheless, after exposure to high sunlight intensity, the anthocyanin produced in the apple peel was dependent on UFGT activity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. System-level line-edge roughness limits in extreme ultraviolet lithography
- Author
-
Zhang, Guojing
- Published
- 2008
24. Lithographic characterization of the printability of programmed EUV substrate defects
- Author
-
Zhang, Guojing
- Published
- 2002
25. Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.
- Author
-
Fan, Jun, Lin, Ruiting, Xia, Siyuan, Chen, Dong, Elf, Shannon E., Liu, Shuangping, Pan, Yaozhu, Xu, Haidong, Qian, Zhiyu, Wang, Mei, Shan, Changliang, Zhou, Lu, Lei, Qun-Ying, Li, Yuancheng, Mao, Hui, Lee, Benjamin H., Sudderth, Jessica, DeBerardinis, Ralph J., Zhang, Guojing, and Owonikoko, Taofeek
- Subjects
- *
TUMOR growth , *ACETYLCOENZYME A , *ACETYLTRANSFERASES , *PYRUVATE dehydrogenase complex , *MITOCHONDRIAL enzymes , *PHOSPHORYLATION - Abstract
Summary Mitochondrial acetyl-CoA acetyltransferase 1 (ACAT1) regulates pyruvate dehydrogenase complex (PDC) by acetylating pyruvate dehydrogenase (PDH) and PDH phosphatase. How ACAT1 is “hijacked” to contribute to the Warburg effect in human cancer remains unclear. We found that active, tetrameric ACAT1 is commonly upregulated in cells stimulated by EGF and in diverse human cancer cells, where ACAT1 tetramers, but not monomers, are phosphorylated and stabilized by enhanced Y407 phosphorylation. Moreover, we identified arecoline hydrobromide (AH) as a covalent ACAT1 inhibitor that binds to and disrupts only ACAT1 tetramers. The resultant AH-bound ACAT1 monomers cannot reform tetramers. Inhibition of tetrameric ACAT1 by abolishing Y407 phosphorylation or AH treatment results in decreased ACAT1 activity, leading to increased PDC flux and oxidative phosphorylation with attenuated cancer cell proliferation and tumor growth. These findings provide a mechanistic understanding of how oncogenic events signal through distinct acetyltransferases to regulate cancer metabolism and suggest ACAT1 as an anti-cancer target. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
- Author
-
Han, Bingshe, Park, Dongkyoo, Li, Rui, Xie, Maohua, Owonikoko, Taofeek K., Zhang, Guojing, Sica, Gabriel L., Ding, Chunyong, Zhou, Jia, Magis, Andrew T., Chen, Zhuo G., Shin, Dong M., Ramalingam, Suresh S., Khuri, Fadlo R., Curran, Walter J., and Deng, Xingming
- Subjects
- *
LUNG cancer treatment , *BCL-2 proteins , *APOPTOSIS inhibition , *ANTINEOPLASTIC agents , *MOLECULAR conformation , *CLINICAL trials - Abstract
Summary The BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a promising anticancer target. We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo. Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
- Author
-
Jin, Lingtao, Chun, Jaemoo, Pan, Chaoyun, Li, Dan, Lin, Ruiting, Alesi, Gina N., Wang, Xu, Kang, Hee-Bum, Song, Lina, Wang, Dongsheng, Zhang, Guojing, Fan, Jun, Boggon, Titus J., Zhou, Lu, Kowalski, Jeanne, Qu, Cheng-Kui, Steuer, Conor E., Chen, Georgia Z., Saba, Nabil F., and Boise, Lawrence H.
- Subjects
- *
CISPLATIN , *CANCER cells , *CANCER patients , *RNA interference , *THREONINE - Abstract
Summary Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance limits their curative potential. Through a kinome RNAi screen, we identified microtubule-associated serine/threonine kinase 1 (MAST1) as a main driver of cisplatin resistance in human cancers. Mechanistically, cisplatin but no other DNA-damaging agents inhibit the MAPK pathway by dissociating cRaf from MEK1, while MAST1 replaces cRaf to reactivate the MAPK pathway in a cRaf-independent manner. We show clinical evidence that expression of MAST1, both initial and cisplatin-induced, contributes to platinum resistance and worse clinical outcome. Targeting MAST1 with lestaurtinib, a recently identified MAST1 inhibitor, restores cisplatin sensitivity, leading to the synergistic attenuation of cancer cell proliferation and tumor growth in human cancer cells and patient-derived xenograft models. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer.
- Author
-
Jin, Lingtao, Chun, Jaemoo, Pan, Chaoyun, Kumar, Avi, Zhang, Guojing, Ha, Youna, Li, Dan, Alesi, Gina N., Kang, Yibin, Zhou, Lu, Yu, Wen-Mei, Magliocca, Kelly R., Khuri, Fadlo R., Qu, Cheng-Kui, Metallo, Christian, Owonikoko, Taofeek K., and Kang, Sumin
- Subjects
- *
LUNG cancer , *CANCER prognosis , *ANOIKIS , *METASTASIS , *CELL communication , *GLUTAMATE dehydrogenase - Abstract
Summary Loss of LKB1 is associated with increased metastasis and poor prognosis in lung cancer, but the development of targeted agents is in its infancy. Here we report that a glutaminolytic enzyme, glutamate dehydrogenase 1 (GDH1), upregulated upon detachment via pleomorphic adenoma gene 1 (PLAG1), provides anti-anoikis and pro-metastatic signals in LKB1-deficient lung cancer. Mechanistically, the GDH1 product α-KG activates CamKK2 by enhancing its substrate AMPK binding, which contributes to energy production that confers anoikis resistance. The effect of GDH1 on AMPK is evident in LKB1-deficient lung cancer, where AMPK activation predominantly depends on CamKK2. Targeting GDH1 with R162 attenuated tumor metastasis in patient-derived xenograft model and correlation studies in lung cancer patients further validated the clinical relevance of our finding. Our study provides insight into the molecular mechanism by which GDH1-mediated metabolic reprogramming of glutaminolysis mediates lung cancer metastasis and offers a therapeutic strategy for patients with LKB1-deficient lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
- Author
-
Zhu L, Chen Z, Zang H, Fan S, Gu J, Zhang G, Sun KD, Wang Q, He Y, Owonikoko TK, Ramalingam SS, and Sun SY
- Subjects
- Animals, Apoptosis drug effects, Apoptosis genetics, Biomarkers, Cell Line, Tumor, Disease Models, Animal, Drug Resistance, Neoplasm genetics, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, Humans, Proteasome Endopeptidase Complex metabolism, Xenograft Model Antitumor Assays, Acrylamides pharmacology, Aniline Compounds pharmacology, Mutation, Protein Kinase Inhibitors pharmacology, Proto-Oncogene Proteins c-myc antagonists & inhibitors
- Abstract
Osimertinib (AZD9291 or TAGRISSO) is a promising and approved third-generation EGFR tyrosine kinase inhibitor (TKI) for treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. However, the inevitable emergence of acquired resistance limits its long-term efficacy. A fuller understanding of the mechanism of action of osimertinib and its linkage to acquired resistance will enable the development of more efficacious therapeutic strategies. Consequently, we have identified a novel connection between osimertinib or other EGFR-TKIs and c-Myc. Osimertinib rapidly and sustainably decreased c-Myc levels primarily via enhancing protein degradation in EGFR-mutant (EGFRm) NSCLC cell lines and xenograft tumors. c-Myc levels were substantially elevated in different EGFRm NSCLC cell lines with acquired resistance to osimertinib in comparison with their corresponding parental cell lines and could not be reduced any further by osimertinib. Consistently, c-Myc levels were elevated in the majority of EGFRm NSCLC tissues relapsed from EGFR-TKI treatment compared with their corresponding untreated baseline c-Myc levels. Suppression of c-Myc through knockdown or pharmacologic targeting with BET inhibitors restored the response of resistant cell lines to osimertinib. These findings indicate that c-Myc modulation mediates the therapeutic efficacy of osimertinib and the development of osimertinib acquired resistance. Furthermore, they establish c-Myc as a potential therapeutic target and warrant clinical testing of BET inhibition as a potential strategy to overcome acquired resistance to osimertinib or other EGFR inhibitors. SIGNIFICANCE: This study demonstrates a critical role of c-Myc modulation in mediating therapeutic efficacy of osimertinib including osimertinib acquired resistance and suggests targeting c-Myc as a potential strategy to overcome osimertinib acquired resistance., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
30. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
- Author
-
Park D, Anisuzzaman ASM, Magis AT, Chen G, Xie M, Zhang G, Behera M, Sica GL, Ramalingam SS, Owonikoko TK, and Deng X
- Subjects
- Animals, Antineoplastic Agents pharmacology, Apoptosis drug effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Humans, Lung Neoplasms pathology, Mice, Mice, Nude, Mitochondria drug effects, Mitochondria metabolism, Peptide Fragments metabolism, Protein Binding, Protein Domains drug effects, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism, Xenograft Model Antitumor Assays methods, Lung Neoplasms therapy, Small Molecule Libraries pharmacology, bcl-2 Homologous Antagonist-Killer Protein metabolism
- Abstract
Rationale: Bak is a major proapoptotic Bcl2 family member and a required molecule for apoptotic cell death. High levels of endogenous Bak were observed in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cell lines. Increased Bak expression was correlated with poor prognosis of NSCLC patients, suggesting that Bak protein is an attractive target for lung cancer therapy. The BH3 domain functions as death domain and is required for Bak to initiate apoptotic cell death. Thus, the BH3 domain is attractive target for discovery of Bak agonist. Methods: The BH3 death domain binding pocket (aa75-88) of Bak was chosen as a docking site for screening of small molecule Bak activators using the UCSF DOCK 6.1 program suite and the NCI chemical library (300,000 small molecules) database. The top 500 compounds determined to have the highest affinity for the BH3 domain were obtained from the NCI and tested for cytotoxicity for further screening. We identified a small molecule Bak activator BKA-073 as the lead compound. The binding affinity of BKA-073 with Bak protein was analyzed by isothermal titration calorimetry (ITC) assay. BKA-073-mediated Bak activation via oligomerization was analyzed by a cross-linking with Bis (maleimido) hexane (BMH). Sensitivity of BKA-073 to lung cancer cells in vitro was evaluated by dynamic BH3 profiling (DBP) and apoptotic cell death assay. The potency of BKA-073 alone or in combination with radiotherapy or Bcl2 inhibitor was evaluated in animal models. Results: We found that BKA-073 binds Bak at BH3 domain with high affinity and selectivity. BKA-073/Bak binding promotes Bak oligomerization and mitochondrial priming that activates its proapoptotic function. BKA-073 potently suppresses tumor growth without significant normal tissue toxicity in small cell lung cancer (SCLC) and NSCLC xenografts, patient-derived xenografts, and genetically engineered mouse models of mutant KRAS-driven cancer. Bak accumulates in radioresistant lung cancer cells and BKA-073 reverses radioresistance. Combination of BKA-073 with Bcl-2 inhibitor venetoclax exhibits strong synergy against lung cancer in vivo. Conclusions: Development of small molecule Bak activator may provide a new class of anticancer agents to treat lung cancer., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2021
- Full Text
- View/download PDF
31. The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer.
- Author
-
Zhang G, Shi Z, Liu L, Yuan H, Pan Z, Li W, Tao Y, Huang Z, Huang X, and Lin C
- Abstract
Background: This study aimed to explore the prognostic function of p53 and Ki-67 protein expression in chemotherapy sensitivity and prognosis in triple-negative breast cancer (TNBC)., Methods: Patients who were confirmed with TNBC in Wenzhou Geriatric Hospital and Wenzhou Hospital of Traditional Chinese Medicine (including the Oncology Department, Tumor Surgery Department, and Gynecology Department) between January 2006 and February 2018 were included in this study. The expression of p53 and Ki-67 detected by immunohistochemistry, the rate of recurrence, and the objective curative effect evaluation at the end of the first-line rescue treatment were recorded for all patients., Results: The patients were followed up to August 2020, and the median follow-up time was 9 years and 4 months. A total of 285 patients with TNBC were enrolled in the study. The patients ranged in age from 19 to 76 years old, with an average age of 53 years. The overall recurrence rate among the patients was 31.58%. The majority of cases (68.07%) were pathological stage I. The overall positive expression rates of Ki-67 and p53 were 53.33% and 56.84%, respectively. In the TNBC recurrence group, the positive rates of p53 and Ki-67 were 71.11% and 82.22%, respectively, which were significantly higher than those in the non-recurrence group. The positive rates of p53 and Ki-67 in the chemosensitive group were 96.05% and 92.11%, respectively, which were significantly higher than those in the non-chemosensitive group. Among all the TNBC patients, 128 patients had positive expression of both p53 and Ki-67, and 101 patients had negative expression of both p53 and Ki-67. The chemosensitivity rate of TNBC patients with positive expression of both Ki-67 and p53 was 98.53%, and that of TNBC patients with negative expression of both Ki-67 and p53 was 0.00%. The difference was statistically significant. The recurrence rate in TNBC patients with positive expression of both Ki-67 and p53 was 53.13%, and that in patients with negative expression of both Ki-67 and p53 was 6.93%. The difference was statistically significant., Conclusions: The expression of p53 and Ki-67 had prognostic relevance to chemotherapy sensitivity and prognosis in TNBC patients., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-21-180). The authors have no conflicts of interest to declare., (2021 Translational Cancer Research. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
32. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
- Author
-
Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, Zhang G, Wang S, Hossain MS, Nazha B, Beardslee T, Khuri FR, Curran W, Lonial S, Waller EK, Ramalingam S, and Owonikoko TK
- Subjects
- Aged, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Combined Chemotherapy Protocols pharmacology, Female, Humans, Lung Neoplasms pathology, Male, Neoplasm Recurrence, Local, Small Cell Lung Carcinoma pathology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Radiosurgery methods, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma radiotherapy
- Abstract
Background: Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as salvage therapy in relapsed small cell lung cancer (SCLC). We conducted this signal-finding study to assess the efficacy of ICB with or without radiation in relapsed SCLC., Methods: Patients with relapsed SCLC and ≤2 previous lines of therapy were randomized to (1) arm A: durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without stereotactic body radiation therapy (SBRT)) or (2) arm B: immune-sensitizing SBRT to one selected tumor site (9 Gy × 3 fractions) followed by D/T. Treatment continued until progression or a maximum of 12 months. The co-primary endpoints of the study were overall response rate (ORR) and progression-free survival (PFS). We evaluated circulating lymphocyte repertoire in serial peripheral blood samples and tumor infiltrating lymphocytes (TILs) from on-treatment biopsies as pharmacodynamic markers., Results: Eighteen patients were randomized to arms A and B (n=9 each): median age 70 years; 41.2% women. The median PFS and ORR were 2.1 months and 0% in arm A and 3.3 months and 28.6% in arm B. The median overall survival (OS) was 2.8 months in arm A and 5.7 months in arm B (p=0.3772). Pooled efficacy of D/T±SBRT in 15 Response evaluation criteria in solid tumors (RECIST) evaluable patients across both arms showed the best ORR in terms of partial response in 13.3%, stable disease in 26.6% and progressive disease in 60.0%; the overall median PFS and OS were 2.76 and 3.9 months. The most common adverse events were grade 1 fatigue (66%) and grade 1 elevated amylase (56%) in arm A, and grade 1 fatigue (56%) and pain (44%) in arm B. There was a significant increase in activated CD8(+)ICOS+ T cells (p=0.048) and a reduction in naïve T cells (p=0.0454) in peripheral blood following treatment, along with a significant amount of activated CD8+ICOS+ T cells in TILs from responders., Conclusions: The D/T combination with and without SBRT was safe but did not show sufficient efficacy signal in relapsed SCLC. Changes in peripheral blood lymphocyte and TILs were consistent with an immunologic response. Trial registration number NCT02701400., Competing Interests: Competing interests: AstraZeneca provided funding for this study and is manufacturing the products being evaluated in the research described in this paper. TKO and KH served as paid consultants to AstraZeneca and personally received compensation for these services. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
33. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
- Author
-
Zong D, Gu J, Cavalcante GC, Yao W, Zhang G, Wang S, Owonikoko TK, He X, and Sun SY
- Subjects
- Animals, Apoptosis drug effects, Cell Line, Tumor, Humans, Lung Neoplasms pathology, Mice, Myeloid Cell Leukemia Sequence 1 Protein metabolism, Thalidomide pharmacology, Xenograft Model Antitumor Assays, Azepines pharmacology, Cell Cycle Proteins metabolism, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Myeloid Cell Leukemia Sequence 1 Protein antagonists & inhibitors, Proteins metabolism, Thalidomide analogs & derivatives, Transcription Factors metabolism, Triazoles pharmacology
- Abstract
Lung cancer consists of approximately 80% non-small cell lung cancer (NSCLC) and 20% small cell lung cancer (SCLC) and remains the leading cause of cancer-related deaths worldwide despite advances in early diagnosis, targeted therapy, and immunotherapy. Thus, novel therapies are still urgently needed. Bromodomain and extraterminal (BET) proteins, primarily comprised of BRD2, BRD3, and BRD4 proteins, function as epigenetic readers and master transcription coactivators and are now recognized cancer therapeutic targets. BET degraders such as ZBC260 and dBET represent a novel class of BET inhibitors that act by inducing BET degradation. The current study demonstrates the therapeutic efficacies of BET degraders, particularly ZBC260, against lung cancer, as well as understanding the underlying mechanisms and identifying molecular markers that determine cell sensitivity to BET degraders. A panel of NSCLC cell lines possessed similar response patterns to ZBC260 and dBET but different responses to BET inhibitor JQ-1. BRD levels, particularly BRD4, correlated positively with high sensitivity to BET degraders but not to JQ-1. BET degraders potently induced apoptosis in sensitive NSCLC cells and were accompanied by reduction of Mcl-1 and c-FLIP levels, which are critical for mediating induction of apoptosis and enhancement of TRAIL-induced apoptosis. Accordingly, ZBC260 exerted more potent activity than JQ-1 in vivo against the growth of NSCLC xenografts and patient-derived xenografts. These findings warrant future clinical validation of the efficacy of BET degraders in NSCLC, particularly those with high levels of BRD proteins, especially BRD4. SIGNIFICANCE: The current study demonstrates the potential of novel BET degraders in the treatment of lung cancer and warrants clinical validation of BET degraders in lung cancer with high levels of BRD4., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
34. Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world.
- Author
-
Li H, Wang J, Zhang G, Li Y, Lin L, Yang H, Zhou J, Zhang L, and Lv D
- Abstract
Background: The epidermal growth factor receptor (EGFR) gene has been identified as the driving gene of non-small cell lung cancer (NSCLC), and EGFR-tyrosine kinase inhibitor (TKI) has shown efficacy, but acquired resistance is inevitable. It has been confirmed that the secondary EGFR Thr790Met (T790M) mutation accounts for about 50% of the mechanisms of acquired resistance to EGFR-TKI. The third-generation of EGFR-TKI has significantly efficacy in advanced T790M-positive NSCLC patients. Therefore, it is necessary to detect the status of T790M in patients with acquired resistance after first generation EGFR-TKI. The objective of this study was to investigate the positive rate of plasma test T790M mutation and its relationship with different clinical characteristics, and the frequency of T790M mutation in advanced EGFR-mutant NSCLC patients with acquired resistance after firstline EGFR-TKI treatment., Methods: Patients from a single clinical center (Taizhou hospital) were recruited prospectively from September 2017 to June 2018. The eligibility criteria of the trial included the following: (I) aged 18 years or older, histologically confirmed NSCLC stage IIIB/st and EGFR mutation positive; (II) progressive disease (PD) after first generation EGFR-TKI by RECIST v1.1, with PFS>3 months; (III) no third generation TKI treatment. All patients signed informed consent, had 10 mL of blood drawn, and were evaluated for the presence of T790M gene by amplification refractory mutation system (ARMS). The study was approved by the Ethics Committee of Taizhou Hospital (ethical batch number: 201637)., Results: A total of 189 patients were included in the analysis. The overall T790M mutation rate of plasma detection was 36.51% (69/189). The positive rate of T790M mutation after the failure of first generation EGFR-TKI treatment was not correlated with the patient's age, sex, and the type of first generation TKI drugs. However, it was related to the mutation type of EGFR in baseline and the mode of progression according to reports by Wu et al. The frequency of T790M mutation among patients with initial exon 19 deletion mutation, exon 21 L858R point mutation, and other mutations were 45.45%, 26.19% and 33.33%, respectively. The mutation rate of T790M in 19del mutant patients was higher than that of L858R mutation and other mutations (P=0.026). The frequency of T790M mutation in local progression patients was 50% after the first generation TKI was resistant to drug treatment: in gradual progression it was 26.92%, and in dramatic progression it was 38.10%. The frequency of T790M mutation of patients with local progression was significantly higher (P=0.031)., Conclusions: The patients with EGFR mutations after the first generation of EGFR-TKI-acquired resistance of NSCLC were evaluated for their plasma EGFR mutation status, and the overall T790M mutation rate of was 36.51%. The frequency of T790M mutation with initial mutation of 19 del was higher than that of L858R mutation and other mutations, and local progression was higher than that in patients with gradual progression and dramatic progression., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare., (2020 Journal of Thoracic Disease. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
35. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
- Author
-
Shi P, Oh YT, Deng L, Zhang G, Qian G, Zhang S, Ren H, Wu G, Legendre B Jr, Anderson E, Ramalingam SS, Owonikoko TK, Chen M, and Sun SY
- Subjects
- Acrylamides adverse effects, Aniline Compounds adverse effects, Animals, Apoptosis drug effects, Bcl-2-Like Protein 11 metabolism, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm genetics, ErbB Receptors antagonists & inhibitors, Humans, MAP Kinase Signaling System drug effects, Mice, Mutation, Myeloid Cell Leukemia Sequence 1 Protein metabolism, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Proteolysis drug effects, Xenograft Model Antitumor Assays, Acrylamides administration & dosage, Aniline Compounds administration & dosage, Bcl-2-Like Protein 11 genetics, Carcinoma, Non-Small-Cell Lung drug therapy, ErbB Receptors genetics, Myeloid Cell Leukemia Sequence 1 Protein genetics
- Abstract
Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the focus of this study. Experimental Design: AZD9219-resistant cell lines were established by exposing sensitive cell lines to AZD9291. Protein alterations were detected with Western blotting. Apoptosis was measured with annexin V/flow cytometry. Growth-inhibitory effects of tested drugs were evaluated in vitro with cell number estimation and colony formation assay and in vivo with mouse xenograft models. Protein degradation was determined by comparing protein half-lives and inhibiting proteasome. Gene knockdown were achieved with siRNA or shRNA. Results: AZD9291 potently induced apoptosis in EGFR-mutant NSCLC cell lines, in which ERK phosphorylation was suppressed accompanied with Bim elevation and Mcl-1 reduction likely due to enhanced Mcl-1 degradation and increased Bim stability. Blocking Bim elevation by gene knockdown or enforcing Mcl-1 expression attenuated or abolished AZD9291-induced apoptosis. Moreover, AZD9291 lost its ability to modulate Bim and Mcl-1 levels in AZD9291-resistant cell lines. The combination of a MEK inhibitor with AZD9291 restores the sensitivity of AZD9291-resistant cells including those with C797S mutation to undergo apoptosis and growth regression in vitro and in vivo Conclusions: Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291. Clin Cancer Res; 23(21); 6567-79. ©2017 AACR ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
36. Anthocyanin concentration depends on the counterbalance between its synthesis and degradation in plum fruit at high temperature.
- Author
-
Niu J, Zhang G, Zhang W, Goltsev V, Sun S, Wang J, Li P, and Ma F
- Subjects
- Cell Respiration, Ethylenes chemistry, Ethylenes metabolism, Hot Temperature, Hydrogen Peroxide metabolism, Phenol chemistry, Plant Extracts chemistry, Proteolysis, Prunus domestica genetics, Transcription, Genetic, Anthocyanins chemistry, Anthocyanins metabolism, Fruit chemistry, Fruit metabolism, Prunus domestica chemistry, Prunus domestica metabolism
- Abstract
Anthocyanin synthesis and degradation processes were analyzed at transcript, enzyme, and metabolite levels to clarify the effects of high temperature on the concentration of anthocyanin in plum fruit (Prunus salicina Lindl.). The transcript levels of PsPAL, PsCHS, and PsDFR decreased while those of PsANS and PsUFGT were similar at 35 °C compared with 20 °C. The activities of the enzymes encoded by these genes were all increased in fruits at 35 °C. The concentrations of anthocyanins were higher at 35 °C on day 5 but then decreased to lower values on day 9 compared with that at 20 °C. Furthermore, high temperature (35 °C) increased the concentration of hydrogen peroxide and the activity of class III peroxidase in the fruit. The concentration of procatechuic acid, a product of the reaction between anthocyanin and hydrogen peroxide, hardly changed at 20 °C but was significantly increased at 35 °C on day 9, indicating that anthocyanin was degraded by hydrogen peroxide, which was catalyzed by class III peroxidase. Based on mathematical modeling, it was estimated that more than 60-70% was enzymatically degraded on day 9 when the temperature increased from 20 °C to 35 °C. We conclude that at the high temperature, the anthocyanin content in plum fruit depend on the counterbalance between its synthesis and degradation.
- Published
- 2017
- Full Text
- View/download PDF
37. Modulation of Bax and mTOR for Cancer Therapeutics.
- Author
-
Li R, Ding C, Zhang J, Xie M, Park D, Ding Y, Chen G, Zhang G, Gilbert-Ross M, Zhou W, Marcus AI, Sun SY, Chen ZG, Sica GL, Ramalingam SS, Magis AT, Fu H, Khuri FR, Curran WJ, Owonikoko TK, Shin DM, Zhou J, and Deng X
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation, Disease Models, Animal, Humans, Lung Neoplasms pathology, Mice, Models, Structural, Phosphorylation, Signal Transduction, Lung Neoplasms genetics, TOR Serine-Threonine Kinases genetics, TOR Serine-Threonine Kinases metabolism, bcl-2-Associated X Protein genetics, bcl-2-Associated X Protein metabolism
- Abstract
A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Here, we report the refinement of the Bax agonist SMBA1 to generate CYD-2-11, which has characteristics of a suitable clinical lead compound. CYD-2-11 targeted the structural pocket proximal to S184 in the C-terminal region of Bax, directly activating its proapoptotic activity by inducing a conformational change enabling formation of Bax homooligomers in mitochondrial membranes. In murine models of small-cell and non-small cell lung cancers, including patient-derived xenograft and the genetically engineered mutant KRAS-driven lung cancer models, CYD-2-11 suppressed malignant growth without evident significant toxicity to normal tissues. In lung cancer patients treated with mTOR inhibitor RAD001, we observed enhanced S184 Bax phosphorylation in lung cancer cells and tissues that inactivates the propaoptotic function of Bax, contributing to rapalog resistance. Combined treatment of CYD-2-11 and RAD001 in murine lung cancer models displayed strong synergistic activity and overcame rapalog resistance in vitro and in vivo Taken together, our findings provide preclinical evidence for a pharmacologic combination of Bax activation and mTOR inhibition as a rational strategy to improve lung cancer treatment. Cancer Res; 77(11); 3001-12. ©2017 AACR ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
38. Distinct Factors Shape Aquatic and Sedimentary Microbial Community Structures in the Lakes of Western China.
- Author
-
Yang J, Jiang H, Wu G, Liu W, and Zhang G
- Abstract
Little is known about the relative importance of spatial and environmental factors to structuring aquatic and sedimentary microbial biogeography in lakes. Here, we investigated the microbial community composition (MCC) of the water ( n = 35) and sediment ( n = 35) samples from 16 lakes in western China (salinity: freshwater to salt saturation; pairwise geographical distance: 9-2027 km) using high-throughput sequencing and evaluated the relative importance of spatial and environmental factors to microbial (including total, abundant, and rare) distributions. Our results showed that spatial factors were more important than environmental factors in shaping the biogeography of aquatic and sedimentary microbial communities in the studied lakes, and spatial factors on abundant microbial community was stronger than that on the total/rare microbial communities. Moreover, sedimentary rare MCC might be more sensitive to environmental factors than its aquatic counterpart. Such different biogeography responses of total, abundant, and rare communities to environmental and spatial factors could be ascribed to different physiochemical properties between water and sediment. Collectively, this study expands our understanding of factors shaping microbial biogeography of total, abundant, and rare communities between waters and sediments of lakes.
- Published
- 2016
- Full Text
- View/download PDF
39. Trastuzumab monotherapy for bone marrow metastasis of breast cancer: A case report.
- Author
-
Xu L, Guo F, Song S, Zhang G, Liu Y, and Xie X
- Abstract
The current study presents the case of a 41-year-old female patient who received modified radical mastectomy and adjuvant chemotherapy and radiotherapy for infiltrating ductal cancer of the left breast. The pathological stage of the disease was IIA. In addition, the patient was negative for the estrogen and progesterone receptors, and human epidermal growth factor receptor-2 gene amplification was identified. At one year following surgery, the patient presented with severe pancytopenia and pain at multiple sites all over the body. Furthermore, the patient's Eastern Cooperative Oncology Group performance status score was 3 and numeric rating scale pain score was 8. The bone marrow puncture indicated bone marrow metastatic cancer, and the positron emission tomography/computed tomography (CT) indicated multiple internal organ metastases and osseous metastasis. Chemotherapy treatment posed great risks due to the patient's poor performance status and severe bone marrow suppression. Therefore, trastuzumab monotherapy was administered at a loading dose of 8 mg/kg and a maintenance dose of 6 mg/kg every three weeks. Following four doses of trastuzumab treatment, the patient's performance status significantly improved and the peripheral blood cell counts had returned to within the normal ranges. Taxol was added to the trastuzumab treatment and seven cycles were completed. No metastatic cancer cells were found in the subsequent bone marrow smear test; however, CT showed metastatic foci in the left lung. Furthermore, the enlarged lymph nodes had subsided and the tumor in the right appendix region had decreased in size by 50%. The patient's disease condition was maintained stable for 11 months.
- Published
- 2014
- Full Text
- View/download PDF
40. A rapid PCR-based method for the identification of ob mutant mice.
- Author
-
Ellett JD, Evans ZP, Zhang G, Chavin KD, and Spyropoulos DD
- Subjects
- Alleles, Animals, DNA genetics, Disease Models, Animal, Genetic Predisposition to Disease genetics, Genotype, Mice, Mice, Obese genetics, Mutation genetics, Obesity genetics, Polymerase Chain Reaction methods
- Abstract
With increasing incidence of obesity, there is greater demand for suitable research and therapeutic models. The ob/ob mouse model develops obesity by 5 weeks of age. Previously, a method using DNA purification, PCR, and restriction digestion of products was devised to identify mice bearing the ob allele. Here, we describe a direct PCR method that requires no DNA purification. Wild-type and ob-specific primers are used under the same conditions in two separate and simultaneously run three-primer PCRs. Standard PCR using the wild-type primer mix produces 191 bp and 104 bp bands in +/+ and ob/+ and only the control 191 bp band in ob/ob animals. The ob-specific primer reaction produces 191 bp and 123 bp bands in ob/+ and ob/ob and only the control 191 bp band in +/+ animals. Phenotypic weight gain in offspring of heterozygous intercrosses was used to validate genotypes. This primer-specific PCR method allows simultaneous identification of +/+, ob/+, and ob/ob genotypes prior to breeding age to facilitate breeding and research studies in an important model of clinical obesity.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.